Oxcarbazepine (Trileptal) monotherapy dramatically improves quality of life in two patients with postherpetic neuralgia refractory to carbamazepine and gabapentin.
Criscuolo
Salvatore
S
Auletta
Caterina
C
Lippi
Stefano
S
Brogi
Filippo
F
Brogi
Amerigo
A
D000368:Aged; D000588:Amines / Q000627:therapeutic use; D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use; D000927:Anticonvulsants / Q000008:administration & dosage; D002220:Carbamazepine / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use; D005260:Female; D000077206:Gabapentin; D006562:Herpes Zoster / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D008297:Male; D009437:Neuralgia / Q000188:drug therapy* / Q000209:etiology*; D000078330:Oxcarbazepine; D011788:Quality of Life; D017211:Treatment Failure; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use
D000588:Amines; D018712:Analgesics, Non-Narcotic; D000927:Anticonvulsants; D003509:Cyclohexanecarboxylic Acids; D002220:Carbamazepine; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D000078330:Oxcarbazepine